Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLC
June 5th 2023Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.
Read More
Lisocabtagene Maraleucel Delivers Deep, Durable Efficacy in Chronic Lymphocytic Leukemia
May 30th 2023Study shows 18.4% of patients with relapsed or refractory chronic lymphocytic leukemia treated with lisocabtagene maraleucel achieved a complete response (CR), with median duration of CR not reached at median follow-up of 21.1 months.
Read More
Expert: Though Patients Don’t Always See Savings With Biosimilars, New Policies Could Improve Access
May 15th 2023Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the role biosimilars are playing in the pharmaceutical market as well as in patient access.
Watch